Medications for obesity management: Effectiveness and value
Authors:
Open Access
- 1 May 2023
- journal article
- editorial
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 29 (5) , 569-575
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 DiabetesDiabetes Care, 2013
- Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adultsObesity, 2013
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized studyInternational Journal of Obesity, 2013
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)Obesity, 2013
- Screening for and Management of Obesity in Adults: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2012
- Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)Obesity, 2012
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD TrialObesity, 2011
- Indirect costs of obesity: a review of the current literatureObesity Reviews, 2008
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Utility of hemoglobin A1c in predicting diabetes riskJournal of General Internal Medicine, 2004